RegenCell BioScience Holdings (RGC)

[shinhari1309]

Investors should turn to Healthcare Defensive Stocks to Weather This Current Sentiment

U.S. stocks extended losses at Tuesday's open as investors mulled disappointing earnings from Walmart and General Motors and braced for results from Big Tech due out after the bell.

The benchmark S&P 500 tumbled 0.6%, while the Dow Jones Industrial Average declined by roughly 100 points, or 0.3%. The technology-heavy Nasdaq Composite fell 1.1%.

Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.

Regencell bioscience, a healthcare company stock was also affected by the market, seeing drops of around 30% from last week’s peak. Investors who are looking to own this stock could find the current price attractive and begin collecting the ticker.
Regencell is a recently IPO in July 2021, and had seen a staggering rise of >300% in share price weeks after being listed.

Regencel Bioscience Holding is a R&D and Commercialize Healthcare company that focusses on treating ADHD, ASD and COVID-19 using Traditional Chinese Medicine (”TCM”) approach.

In the past, the company had been through rainy and rough days of being shorted by both short sellers and traders alike which had been strategically planned. Some journalists even compared the short attacked to be identical or even more severe than what happened to the infamous GameStop (GME)

The Company CEO, a practicing TCM practitioner (Mr Au) did not taken this event without a stand. Mr Au has voiced out “Short and distort schemes used on our stock are negatively affecting our company. These schemes hurt our investors and patients, especially children and their families who are looking for a natural approach to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19, and have the potential to disrupt our mission to help our patients.”

[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]

Mr Au took further response by buying back over 5 million ordinary shares to defend the company against these short sellers and has also announced that he will not be drawing salary nor bonus (<1$) until the company reaches $1 Billion USD.

Further stance were taken by the company’s directors and employees where stock options which were previously granted upon company IPO will be subjected to a lock-up of 6 months vesting period. The shares will be locked up until January 16, 2023.